VolitionRx posts corporate deck presentation on Nu.Q diagnostics strategy

Reuters2026/09/10 11:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

VolitionRX published a corporate presentation outlining its Nu.Q nucleosome platform across cancer, sepsis, NETosis, veterinary diagnostics.
Animal-health business cited USD 23 million in licensing revenue; reported USD 1.4 million of revenue in H1 2026.
Presentation flagged a potential USD 5 million contractual milestone tied to feline use, contingent on publication of a submitted cat paper.
Sepsis program positioned for commercial launch in Q3 2026; reimbursement submission described as in preparation.
Strategy emphasizes IP out-licensing with milestone payments, component sales, royalties; cited 74 granted patents with coverage up to 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

VolitionRx posts corporate deck presentation on Nu.Q diagnostics strategy

You may also like

Crypto prices